苯并咪唑类药物新剂型及其抗棘球蚴活性研究进展  

Advances in new benzimidazole formulations and their anti-Echinococcus activities

作　　者：杨海山 双杰 李永臻 Yang Haishan;Shuang Jie;Li Yongzhen(Research Center of Basic Medical Science,Medical College,Qinghai University,Xining 810016,China)

机构地区：[1]青海大学医学院基础医学研究中心,西宁810016

出　　处：《中华地方病学杂志》2021年第6期507-512,共6页Chinese Journal of Endemiology

基　　金：青海省科技计划项目(2018-ZJ-937Q)。

摘　　要：棘球蚴病是棘球绦虫的幼虫(棘球蚴)寄生在人体所致的一种严重的人兽共患寄生虫病。手术治疗作为棘球蚴病首选治疗方式,存在适用范围小、难以完全切除、术后复发率高及患者负担重等缺陷。而药物治疗不仅是棘球蚴病患者术前、术中和术后治疗所必需的,更是手术不适用情况下的首要选择。本文结合苯并咪唑类药物的理化特性、药代性质,对苯并咪唑类药物新剂型的抗棘球蚴活性做一综述,为今后探索棘球蚴病治疗药物提供参考。Echinococcosis is a serious zoonosis parasitic disease caused by the parasitic larva of Echinococcus.Surgical treatment,as the preferred treatment of echinococcosis,has disadvantages such as small scope of application,difficulty in complete resection,high postoperative recurrence rate and heavy burden on patients.Drug therapy is not only a necessary supplement to the preoperative,intraoperative and postoperative treatment of echinococcosis patients,but also the first choice when surgical treatment is not applicable.This article reviews the physicochemical and pharmacokinetic properties of benzimidazole drugs,and summarizes the anti-Echinococcus activities of different benzimidazole formulations,it will provide a reference for future exploration of echinococcosis treatment drugs.

关 键 词：棘球蚴病 苯并咪唑类 理化特性 新剂型 药物治疗 

分 类 号：R978.6[医药卫生—药品]